Aviceda Therapeutics
Cambridge
About Aviceda Therapeutics
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination of cutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation. Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $276.8M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2025)
- Website: avicedarx.com
- Phone: 617-332-0741
Industries & Categories
Biotechnology, Health Care, Life Science, Neuroscience, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/aviceda-therapeutics-88121 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.